Loading...
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Vale, C Burdett, S Rydzewska, L Albiges, L Clarke, Noel W Fisher, D Fizazi, K Gravis, G James, N Mason, M
Vale, C
Burdett, S
Rydzewska, L
Albiges, L
Clarke, Noel W
Fisher, D
Fizazi, K
Gravis, G
James, N
Mason, M
Citations
Altmetric:
Abstract
Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, we aimed to systematically review all relevant trials using a framework for adaptive meta-analysis.
Affiliation
Description
Date
2015-12-21
Publisher
Collections
Keywords
Type
Article
Citation
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. 2015: Lancet Oncol